arrow_back Back to App

Accelerating Research and Access to ALS Drugs

This law aims to accelerate research into Amyotrophic Lateral Sclerosis (ALS) and other rare neurodegenerative diseases. It facilitates access to investigational drugs for patients not eligible for clinical trials and supports the development of new therapies. This provides greater hope for improved quality of life and access to innovative treatments for individuals suffering from these conditions.
Key points
Authorizes grants for scientific research using data from expanded access to investigational drugs for ALS patients.
Establishes a public-private partnership to accelerate the development of therapies for rare neurodegenerative diseases.
Requires the Food and Drug Administration (FDA) to publish an action plan for fostering safe and effective drug development for ALS and other rare neurodegenerative diseases.
Authorizes $100 million annually for fiscal years 2022 through 2026 to carry out the Act.
article Official text account_balance Process page
VOTING RESULTS
2021-12-09
99%
For 423
Against 3
Abstain 0
Full voting results open_in_new
Became Law
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_3537
Sponsor: Rep. Quigley, Mike [D-IL-5]
Process start date: 2021-05-25
Voting date: 2021-12-09
Meeting no: 1
Voting no: 415
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Accelerating Access to Critical Therapies for ALS Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_3537.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2021-05-25.

What are the main provisions?

Key points include:

  • Authorizes grants for scientific research using data from expanded access to investigational drugs for ALS patients.
  • Establishes a public-private partnership to accelerate the development of therapies for rare neurodegenerative diseases.
  • Requires the Food and Drug Administration (FDA) to publish an action plan for fostering safe and effective drug development for ALS and other rare neurodegenerative diseases.
  • Authorizes $100 million annually for fiscal years 2022 through 2026 to carry out the Act.
What is the specific legal status?

The current status is Became Law.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Where is the official voting record?

The official roll call vote is recorded at: voting record

Who is the primary sponsor?

The primary sponsor is Rep. Quigley, Mike [D-IL-5].

What is the latest detailed status?

The latest detailed status is: Became Public Law No: 117-79.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

CATEGORIES

Health